Copy Link Print Information

LY341495

14 Cited Publications
Customer Review

Based on 14 publication(s) in Google Scholar

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively.

For research use only. We do not sell to patients.

  • Purity: 99.17%
  • CAS No.: 201943-63-7
  • Formula: C20H19NO5
  • Molecular Weight:353.37
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • LY341495 Chemical Structure
    LY341495 Chemical Structure
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
  • Experimental Validation Results for LY341495
CAS No.: 201943-63-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of LY341495:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) LY341495

More
Customer Validation & Images
In Vivo Efficacy StudyWBIHCIF
  • WB
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • IHC
  • WB
  • IF
  • WB

All mGluR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • LY341495 Chemical Structure
    LY341495 Chemical Structure
    1/16
  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Mar;35(3):165-185. [Abstract]

    Customer Validation
     Representative western blot and quantification of AKT signal in GT1-7 cells treated with 10 ng/ml Raptin and GRM3 agonists (LY354740, LY2794193, LY379268), inhibitors (LY341495) or allosteric agents (VU0650786).

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Feb 28;11:183. [Abstract]

    Customer Validation
     LY341495 (1 mg/kg; IP; 30 min prior to MPTP injection (30 mg/kg/d) once a day for 7 days consecutively) significantly decreased compared with the normal + saline group and a significant longer time-down (TLA) was spent by the MPTP + saline group and MPTP + LY341495 group compared with the normal + saline group (both p < 0.01) and LY354740 + saline group (both p < 0.05).

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Feb 28;11:183. [Abstract]

    Customer Validation
     LY341495 (1 mg/kg; IP; for four times (30 min before each MPTP injection); once a day for 6 days consecutively) showed that latency times in acute MPTP-mice treated with LY341495 (1 mg/kg) significantly decreased, both MPTP + saline group and MPTP + LY341495 group exhibited longer times (Turn) than normal + saline group and MPTP + LY354740 (4 mg/kg) group.

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Feb 28;11:183. [Abstract]

    Customer Validation
     (A, B) Immunohistochemical images and corresponding TH positive cell counts in SN from each group.LY341495 (1 mg/kg; IP; 30 min prior to MPTP injection (30 mg/kg/d) once a day for 7 days consecutively) counted fewer TH-positive cells in sub-acute MPTP-mice treated.

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Feb 28;11:183. [Abstract]

    Customer Validation
     LY341495 (1 mg/kg; IP; 30 min prior to MPTP injection (30 mg/kg/d) once a day for 7 days consecutively) exhibited much higher expressions of p-Fyn Tyr416.

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Feb 28;11:183. [Abstract]

    Customer Validation
     LY341495 (1 mg/kg; IP; 30 min prior to MPTP injection (30 mg/kg/d) once a day for 7 days consecutively) showed an elevation of the number of PLK2 positive cells, indicating increased expression of PLK2. Immunofluorescence of PLK2 positive cell counts in SN.

  • 1/16

    LY341495 purchased from MedChemExpress. Usage Cited in: Pain. 2016 Aug;157(8):1711-23. [Abstract]

    Customer Validation
     LY341495 and Sulfasalazine mildly suppress the effects of chronic constrictive injury (CCI)-induced mechanical allodynia and matrix metalloproteinase-9 activity by N-acetyl-cysteine (NAC).

  • LY341495